New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2013
06:07 EDTMSFT, IBM, DELL, BA, BRK.A, EMCOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Boeing (BA) offered a strong defense of its grounded 787 Dreamliner, spelled out details of proposed battery fixes and predicted the jets could be back in commercial service in a matter of weeks, the Wall Street Journal reports...Dallas Fed President Richard Fisher will address this year's Conservative Political Action Conference, an unusually political venue for a U.S. central banker, pushing his proposal to break up the biggest U.S. banks as the best way to avoid government bailouts of such firms, the Wall Street Journal reports...REUTERS: IBM (IBM) and EMC Corp. (EMC) are among firms in talks to buy privately held database web hosting company SoftLayer Technologies Inc, in a deal that could be over $2B, sources say, reports Reuters...Silver Lake Partners, the technology-focused private equity firm backing a $24.4B bid to take Dell (DELL) private, is close to raising $10B for its latest fund, exceeding its initial fundraising target on strong investor demand and confidence in the firm, sources say, Reuters reports...BLOOMBERG: Microsoft (MSFT) has sold about 1.5M Surface devices, sources say, a slow beginning in its bid to crack the tablet market to make up for slumping PC demand, Bloomberg reports...Chinese carmaker BYD Co., partially owned by Berkshire Hathaway (BRK.A), plans to sell new shares equivalent to as much as 20% of its Hong Kong-traded stock, sources say, reports Bloomberg.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use